Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 Dec;58(6):810–814. doi: 10.1038/bjc.1988.315

Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.

S Nicholson 1, P Halcrow 1, J R Sainsbury 1, B Angus 1, P Chambers 1, J R Farndon 1, A L Harris 1
PMCID: PMC2246869  PMID: 3224082

Abstract

We have used primary endocrine therapy for 61 elderly women with operable breast cancer (median age 77 years). Eleven patients (18%) had complete and 24 (39%) partial tumour regression, 12 (20%) had stable disease for a minimum of six months and 14 (23%) no response. Salvage surgery was undertaken in the 14 with no response and 8/9 with progressive disease following initial response, thus samples were available from relapse patients only. Assays for EGFr (two point radioreceptor assay) and oestrogen receptors (ER) (dextran coated charcoal method and an immunohistochemical method) were performed on 20/22 patients. Ten of these 20 tumours were EGFr+ (greater than 10 fmol mg-1 binding) and 9/13 patients progressing within six months had EGFr+ tumours. 15/22 were available for ER evaluation and there was no such association with ER status. EGFr status was also associated with early recurrence after surgery and death in the endocrine failure group (P less than 0.005 and P less than 0.05 respectively). Of a control population of 33 patients (median age 72 years) treated by primary surgery, only 6 were EGFr+. In this group early relapse was predicted by EGFr status, but not by ER status (median disease free survival for EGFr+ patients 15 months, and for EGFr- patients 40 months, P less than 0.01, logrank test). There was a significantly higher proportion of EGFr+ tumours in the endocrine failure group compared with the control population (P less than 0.001). EGFr status is a marker for rapid early progression on primary endocrine therapy and the development of non-excisional methods of EGFr analysis would allow better directed therapeutic decisions.

Full text

PDF
810

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan S. G., Rodger A., Smyth J. F., Leonard R. C., Chetty U., Forrest A. P. Tamoxifen as primary treatment of breast cancer in elderly or frail patients: a practical management. Br Med J (Clin Res Ed) 1985 Feb 2;290(6465):358–358. doi: 10.1136/bmj.290.6465.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Allegra J. C., Lippman M. E., Thompson E. B., Simon R., Barlock A., Green L., Huff K. K., Do H. M., Aitken S. C. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res. 1979 May;39(5):1447–1454. [PubMed] [Google Scholar]
  3. Block G. E., Jensen E. V., Polley T. Z. The prediction of hormonal dependency of mammary cancer. Ann Surg. 1975 Sep;182(3):342–352. doi: 10.1097/00000658-197509000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Crawford D. J., Cowan S., Fitch R., Smith D. C., Leake R. E. Stability of oestrogen receptor status in sequential biopsies from patients with breast cancer. Br J Cancer. 1987 Aug;56(2):137–140. doi: 10.1038/bjc.1987.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Elwood J. M., Godolphin W. Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients. Br J Cancer. 1980 Nov;42(5):635–644. doi: 10.1038/bjc.1980.296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gazet J. C., Markopoulos C., Ford H. T., Coombes R. C., Bland J. M., Dixon R. C. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet. 1988 Mar 26;1(8587):679–681. doi: 10.1016/s0140-6736(88)91478-x. [DOI] [PubMed] [Google Scholar]
  7. Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  8. Helleberg A., Lundgren B., Norin T., Sander S. Treatment of early localized breast cancer in elderly patients by Tamoxifen. Br J Radiol. 1982 Jul;55(655):511–515. doi: 10.1259/0007-1285-55-655-511. [DOI] [PubMed] [Google Scholar]
  9. Hull D. F., 3rd, Clark G. M., Osborne C. K., Chamness G. C., Knight W. A., 3rd, McGuire W. L. Multiple estrogen receptor assays in human breast cancer. Cancer Res. 1983 Jan;43(1):413–416. [PubMed] [Google Scholar]
  10. Legha S. S., Davis H. L., Muggia F. M. Hormonal therapy of breast cancer: new approaches and concepts. Ann Intern Med. 1978 Jan;88(1):69–77. doi: 10.7326/0003-4819-88-1-69. [DOI] [PubMed] [Google Scholar]
  11. Murray R. M., Pitt P. Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment. Breast Cancer Res Treat. 1981;1(2):91–95. doi: 10.1007/BF01805860. [DOI] [PubMed] [Google Scholar]
  12. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Preece P. E., Wood R. A., Mackie C. R., Cuschieri A. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res Ed) 1982 Mar 20;284(6319):869–870. doi: 10.1136/bmj.284.6319.869-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Roberts M. M., Rubens R. D., King R. J., Hawkins R. A., Millis R. R., Hayward J. L., Forrest A. P. Oestrogen receptors and the response to endocrine therapy in advanced breast cancer. Br J Cancer. 1978 Sep;38(3):431–436. doi: 10.1038/bjc.1978.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sainsbury J. R., Farndon J. R., Needham G. K., Malcolm A. J., Harris A. L. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987 Jun 20;1(8547):1398–1402. doi: 10.1016/s0140-6736(87)90593-9. [DOI] [PubMed] [Google Scholar]
  16. Ward H. W. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J. 1973 Jan 6;1(5844):13–14. doi: 10.1136/bmj.1.5844.13. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES